AdaptHealth exits its Diabetes Health business in a $235 million deal as Cardinal Health expands its diabetes platform and integration strategy.
Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.
Dive deeper
Seven questions, 60-second thesis frame.
What changed, and when
AdaptHealth announced on 20 July 2026 that it had agreed to sell its Diabetes Health business to Cardinal Health for $235 million in cash, subject to purchase-price adjustments. The agreement was signed on 19 July 2026 and requires Hart-Scott-Rodino clearance and other customary closing conditions. (AdaptHealth transaction announcement, finance.yahoo.com)
Cardinal Health announced the acquisition alongside a separate purchase of Strive Medical. The two transactions total approximately $360 million, implying roughly $125 million for Strive, although Cardinal Health did not present that implied figure as a separately disclosed purchase price. (Cardinal Health announcement, Reuters transaction report, reuters.com)
60-second thesis frame
The transaction looks less like AdaptHealth selling a growth crown jewel and more like a portfolio reset around a deteriorating asset. Diabetes Health generated $592.4 million of 2025 revenue, down 3.6%, while adjusted EBITDA fell 56.9% to $26.1 million, leaving a 4.4% margin. AdaptHealth also recorded a $128 million goodwill impairment against the reporting unit. At the headline price, Cardinal Health is paying roughly 0.4 times 2025 revenue and 9.0 times reported segment adjusted EBITDA, before purchase-price adjustments and any separation effects. (AdaptHealth 2025 Form 10-K, sec.gov)
Confidence rises if AdaptHealth uses the proceeds to reduce debt, eliminates stranded costs quickly, and concentrates management attention on the stronger Respiratory Health and Sleep Health franchises. Confidence falls if the divestiture leaves material corporate overhead behind or signals that payer-mix pressure is spreading across the wider platform. For Cardinal Health, the opportunity is to combine AdaptHealth’s direct-to-patient diabetes operations with Advanced Diabetes Supply, acquired in April 2025, and restore profitability through purchasing scale, logistics density, reimbursement expertise, and platform consolidation. (Cardinal Health ADSG completion announcement, Reuters transaction report, reuters.com)
The seven diligence questions
Financial quality
- What is the business’s normalized standalone EBITDA after removing AdaptHealth allocations, one-time remediation costs, and any services retained under transition agreements?
- How much of the $235 million gross consideration becomes net debt reduction after taxes, transaction expenses, working-capital adjustments, and separation costs?
Payer or Access
- Can Cardinal Health reverse the adverse shift from commercial insurance toward lower-yield government payers without impairing patient growth or service levels? AdaptHealth attributed the segment’s 2025 revenue decline primarily to payer-mix deterioration, partly offset by growth in insulin-pump patients and supplies. (AdaptHealth 2025 Form 10-K, sec.gov)
- How exposed is the acquired platform to Medicare documentation requirements, prior authorization, competitive bidding, reimbursement resets, manufacturer channel changes, and payer concentration?
Ops or Adoption
- Can Cardinal Health integrate patient onboarding, billing, fulfilment, clinical support, data, and supplier contracts without disrupting recurring CGM and insulin-pump resupply?
Competitive
- Does combining the business with Advanced Diabetes Supply create defensible scale, or merely consolidate two platforms exposed to the same reimbursement, manufacturer, and customer-acquisition pressures? Cardinal Health’s existing ADSG operation serves approximately 500,000 patients annually. (Cardinal Health ADSG completion announcement, newsroom.cardinalhealth.com)
Team or Cap table
- Which executives, payer-contracting specialists, clinicians, and revenue-cycle leaders transfer with the business, and what measurable capital-allocation targets will AdaptHealth set for the proceeds?
Red flags
- Stranded-cost failure: AdaptHealth’s reported Diabetes Health EBITDA included allocated corporate functions. If those costs remain after closing, consolidated margin and free-cash-flow improvement may materially lag the apparent disposal economics. (AdaptHealth 2025 Form 10-K, sec.gov)
- Turnaround failure: Diabetes Health’s adjusted EBITDA declined from $60.5 million in 2024 to $26.1 million in 2025. Continued payer-mix pressure or service disruption could prevent Cardinal Health from achieving first-year earnings accretion. (AdaptHealth 2025 Form 10-K, Reuters transaction report, reuters.com)
- Concentration risk: Cardinal Health is adding another national diabetes-supply platform shortly after acquiring ADSG for approximately $1.1 billion. Antitrust remedies, overlapping operations, manufacturer dependence, or integration complexity could erode the strategic logic. (Cardinal Health ADSG acquisition announcement, Cardinal Health ADSG completion announcement, prnewswire.com)
Next catalyst
Regulatory clearance and closing guidance: monitor the Hart-Scott-Rodino review, definitive closing timing, net proceeds, debt repayment, transition-service arrangements, and any revised AdaptHealth 2026 guidance in the companies’ next SEC filings and earnings updates. (AdaptHealth transaction announcement, finance.yahoo.com)
FAQ
What exactly changed through AdaptHealth’s Diabetes Health divestiture announced on 20 July 2026?
AdaptHealth entered into a definitive agreement to sell the business to Cardinal Health for $235 million in cash, subject to customary purchase-price adjustments. The unit supplies continuous glucose monitors, insulin pumps, and related direct-to-patient diabetes products and services. (AdaptHealth transaction announcement, Reuters transaction report, reuters.com)
The sale removes a sizeable but low-margin segment from AdaptHealth and expands Cardinal Health’s direct-to-patient home-care platform.
Why is Cardinal Health acquiring AdaptHealth’s Diabetes Health business after already buying Advanced Diabetes Supply?
Cardinal Health completed its approximately $1.1 billion acquisition of Advanced Diabetes Supply Group on 1 April 2025. ADSG serves approximately 500,000 patients annually and was integrated into Cardinal Health’s at-Home Solutions business. (Cardinal Health ADSG completion announcement, newsroom.cardinalhealth.com)
The AdaptHealth transaction adds another direct-to-patient diabetes platform, potentially increasing procurement leverage, fulfilment density, payer capabilities, and patient reach. Cardinal Health says the two newly announced acquisitions are expected to be accretive to adjusted earnings per share during their first 12 months after closing. (Reuters transaction report, reuters.com)
What financial performance preceded AdaptHealth’s 20 July 2026 divestiture announcement?
Diabetes Health produced $592.4 million of revenue in 2025, compared with $614.4 million in 2024. Adjusted EBITDA declined from $60.5 million to $26.1 million, and its margin contracted from 9.9% to 4.4%. (AdaptHealth 2025 Form 10-K, sec.gov)
AdaptHealth attributed the revenue decline principally to a shift from commercial insurance toward government payers. It also recognized a $128 million non-cash goodwill impairment for the Diabetes Health reporting unit. (AdaptHealth 2025 Form 10-K, sec.gov)
What regulatory steps follow the AdaptHealth–Cardinal Health agreement announced on 20 July 2026?
The transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to customary closing conditions. The public announcement did not provide a final clearance date. (AdaptHealth transaction announcement, finance.yahoo.com)
The main regulatory diligence issue is whether Cardinal Health’s ownership of ADSG and the AdaptHealth diabetes platform creates meaningful concentration in any product, payer, geography, or direct-to-patient channel.
How should investors interpret the $360 million figure reported alongside the 20 July 2026 announcement?
The $360 million figure refers to Cardinal Health’s combined cash consideration for two separate acquisitions, AdaptHealth’s Diabetes Health business and Strive Medical. AdaptHealth’s portion is explicitly priced at $235 million. (Cardinal Health announcement, Reuters transaction report, reuters.com)
The approximately $125 million difference is an arithmetic inference for Strive Medical, not a separately confirmed price in the sources reviewed. The $235 million Diabetes Health price is therefore the appropriate figure for assessing AdaptHealth’s divestiture.
Publisher / Disclosure
Publisher: LucidQuest Ventures Ltd. Produced: 21 Jul 2026, 06:42 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.
Entities / Keywords
AdaptHealth; Cardinal Health; Diabetes Health; Advanced Diabetes Supply Group; ADSG; Strive Medical; AHCO; CAH; continuous glucose monitoring; CGM; insulin pumps; diabetes supplies; durable medical equipment; DME; home medical equipment; at-Home Solutions; direct-to-patient; Medicare; Medicaid; commercial insurance; government payers; payer mix; prior authorization; reimbursement; revenue-cycle management; Hart-Scott-Rodino; HSR review; antitrust; debt reduction; portfolio simplification; adjusted EBITDA; goodwill impairment; stranded costs; transition services; home healthcare; United States
Reach out to info@lqventures.com for a customized / deeper-level analysis.